JP2023536904A5 - - Google Patents
Info
- Publication number
- JP2023536904A5 JP2023536904A5 JP2023507563A JP2023507563A JP2023536904A5 JP 2023536904 A5 JP2023536904 A5 JP 2023536904A5 JP 2023507563 A JP2023507563 A JP 2023507563A JP 2023507563 A JP2023507563 A JP 2023507563A JP 2023536904 A5 JP2023536904 A5 JP 2023536904A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- amino acid
- acid sequence
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062243P | 2020-08-06 | 2020-08-06 | |
| US63/062,243 | 2020-08-06 | ||
| PCT/US2021/044761 WO2022031978A1 (en) | 2020-08-06 | 2021-08-05 | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023536904A JP2023536904A (ja) | 2023-08-30 |
| JP2023536904A5 true JP2023536904A5 (enExample) | 2024-12-16 |
Family
ID=77750323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507563A Pending JP2023536904A (ja) | 2020-08-06 | 2021-08-05 | 補体が媒介する疾患を有する対象における炎症性サイトカインおよび疲労 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230357433A1 (enExample) |
| EP (1) | EP4193153A1 (enExample) |
| JP (1) | JP2023536904A (enExample) |
| KR (1) | KR20230044312A (enExample) |
| CN (1) | CN116724236A (enExample) |
| AU (1) | AU2021320870A1 (enExample) |
| BR (1) | BR112023001942A2 (enExample) |
| CA (1) | CA3187866A1 (enExample) |
| IL (1) | IL300376A (enExample) |
| MX (1) | MX2023001492A (enExample) |
| WO (1) | WO2022031978A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3722320A3 (en) | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| CN110300520B (zh) | 2016-10-12 | 2022-10-04 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| WO2022212645A1 (en) * | 2021-03-31 | 2022-10-06 | Bioverativ Usa Inc. | Reducing surgery-associated hemolysis in cold agglutinin disease patients |
| US20240117021A1 (en) * | 2022-06-15 | 2024-04-11 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
| CA3260415A1 (en) * | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | METHODS OF TREATMENT FOR COMPLEMENT-MEDICATED DISEASES |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| EP2997045A4 (en) * | 2013-05-15 | 2016-11-23 | Annexon Inc | ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF |
| CA2981321A1 (en) | 2015-04-06 | 2016-10-13 | True North Therapeutics, Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| MX2017016835A (es) * | 2015-06-26 | 2018-08-01 | Bioverativ Usa Inc | Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios. |
| US11464810B2 (en) * | 2016-08-25 | 2022-10-11 | California Institute Of Technology | Ascaroside treatment of eosinophilic esophagitis |
| CN110300520B (zh) * | 2016-10-12 | 2022-10-04 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| CR20190468A (es) | 2017-03-14 | 2019-12-17 | Bioverativ Usa Inc | Métodos para tratar enfermedades y trastornos mediados por completo |
| EP3774892A4 (en) * | 2018-04-13 | 2022-02-16 | Chugai Seiyaku Kabushiki Kaisha | ANTI-COMPLEMENT COMPONENT ANTIBODIES AND METHODS OF USE |
| JP7499760B2 (ja) * | 2018-11-02 | 2024-06-14 | アネクソン，インコーポレーテッド | 脳損傷を治療するための組成物及び方法 |
-
2021
- 2021-08-05 IL IL300376A patent/IL300376A/en unknown
- 2021-08-05 BR BR112023001942A patent/BR112023001942A2/pt unknown
- 2021-08-05 MX MX2023001492A patent/MX2023001492A/es unknown
- 2021-08-05 CN CN202180056699.1A patent/CN116724236A/zh active Pending
- 2021-08-05 KR KR1020237007908A patent/KR20230044312A/ko active Pending
- 2021-08-05 AU AU2021320870A patent/AU2021320870A1/en active Pending
- 2021-08-05 JP JP2023507563A patent/JP2023536904A/ja active Pending
- 2021-08-05 WO PCT/US2021/044761 patent/WO2022031978A1/en not_active Ceased
- 2021-08-05 EP EP21770091.3A patent/EP4193153A1/en active Pending
- 2021-08-05 CA CA3187866A patent/CA3187866A1/en active Pending
-
2023
- 2023-02-03 US US18/164,521 patent/US20230357433A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023536904A5 (enExample) | ||
| ES2535365T3 (es) | Tratamiento de trastornos relacionados con TNF alfa | |
| JP2020522261A5 (enExample) | ||
| CN108404127B (zh) | 恶病质治疗 | |
| JP2019523295A5 (enExample) | ||
| JP2014509510A5 (enExample) | ||
| SI3064511T1 (en) | THE MEDICINE USE OF HUMAN HIGHLIGHTS FOR HUMAN RECEPTOR IL-4 | |
| RU2018131123A (ru) | Антитела к tgf-бета2 | |
| JP2016094424A5 (enExample) | ||
| JP2023528441A5 (enExample) | ||
| CN109983032A (zh) | Tim-3抗体、其抗原结合片段及医药用途 | |
| KR20210071944A (ko) | 인플라마솜 관련 질환 또는 상태 치료용 조성물 및 방법 | |
| TW202413423A (zh) | 靶向胸腺基質淋巴細胞生成素（ｔｓｌｐ）之抗原結合分子 | |
| KR20240034228A (ko) | 아토피성 피부염의 치료를 위한 il-13 항체 | |
| JP2014515743A (ja) | Ｔｇｆ−アルファおよびエピレグリンに結合する抗体 | |
| JP2022541646A5 (enExample) | ||
| TW202523689A (zh) | 治療脊髓損傷及疼痛之方法 | |
| JP7610767B2 (ja) | レット症候群の処置のためのセマフォリン４ｄ結合分子の使用 | |
| RU2023104423A (ru) | Воспалительные цитокины и утомляемость у субъекта с опосредованным комплементом заболеванием | |
| JP2019531254A5 (enExample) | ||
| JPWO2020218232A5 (enExample) | ||
| KR102959210B1 (ko) | 레트 증후군의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| RU2844863C1 (ru) | Применение молекул, связывающих семафорин-4d, для лечения синдрома ретта | |
| JP2019519470A5 (enExample) | ||
| RU2021104860A (ru) | Антитела против CXCR2 и их применение |